T Rowe Price purchased 7,940,960 shares in the 1st Quarter. The range of pricing would have been anywhere between $13.93 - $22.59. For the sake of argument, let's assume they purchased those shares for $20.65 during the share offering in March. If they kept all of those shares, that means they made approximately $50 million dollars on that 1st Quarter investment. Well done T. Rowe Price analysts. Let me be the first one to wish you similar returns in the third quarter.
Someone posted something within the last month or so about a conference that Insmed is participating in September. Does anyone remember this and can you post the information? I can't seem to find it.
Yes, this is an article on The Street by Adam Feuerstein on 10/22/13 I'm not against in people posting information from the past for people to round out their dd......but not putting dates on the information is very misleading. Desperate, indeed......8-)
......the Institution 2nd quarter reports of 6/30 are trickling in. American Century Companies is a NEW investor with 57,814 shares. I hope their analysts did some good dd..........8-)
Dated which Tuesday......May 12th.....2 1/2 months ago? I may be guessing here, thus could be wrong, but I gathered that was an options transaction??? Acquired at the price of $15.61 and disposed at a price of $22.07 He still has 31,250 shares. Perhaps you could provide some clarification as to your post.
FMJ.......I especially agree with your last two sentences. Several here have said that it's the "tutes" that are in control......and I realistically agree. But I'm also hoping that those in charge of the 87 "tutes" have , at the very least, read Peter Lynch's book "Institutional Investing: 101".......well, at least I wish he wrote a book like that......8-). Does anyone have the ear of Warren Buffett? Maybe he would be happy to buyout the shares of the "tutes" who don't have the sense to stick around.
........some things to google and do some DD. Must be some good reasons why Fidelity is invested heavily in Insmed. Insmed has 87% of their shares owned by institutions. What have their analysts discovered in their due diligence?
When I googled the EMEA number, I found the following. Is this helpful?
3.3.2. - amikacin - Orphan - EMEA/H/C/003936
Insmed Limited; treatment of Pseudomonas aeruginosa lung infection/colonisation in cystic fibrosis patients, treatment of nontuberculous mycobacterial lung infection
Scope: Day 120 list of questions and revised timetable on similarity assessment
Action: For adoption
....this report was released today after-hours.....UP approximately 150,000 shares
Avg Daily Share Volume
Days To Cover
7/15/2015 4,579,967 313,615 14.603788
6/30/2015 4,430,273 503,843 8.792963
So, I am assuming you have used the same strategy with regards to your Insmed holdings?